Role of carglumic acid in the long-term management of propionic and methylmalonic acidurias
2024

Carglumic Acid for Managing Rare Metabolic Disorders

Sample size: 38 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yap Sufin, Gasperini Serena, Matsumoto Shirou, Feillet François

Hypothesis

Can carglumic acid improve long-term management outcomes for patients with propionic and methylmalonic acidurias?

Conclusion

Carglumic acid is safe and effective for the chronic treatment of propionic and methylmalonic acidurias, potentially reducing hospital admissions and hyperammonemic episodes.

Supporting Evidence

  • Carglumic acid significantly reduced emergency room admissions by 51% over two years.
  • Patients receiving carglumic acid had fewer hospital admission days compared to those on standard treatment.
  • Clinical studies showed a reduction in hyperammonemic episodes with the addition of carglumic acid.

Takeaway

Carglumic acid helps kids with certain rare diseases by keeping their ammonia levels normal, which makes them feel better and stay out of the hospital.

Methodology

The study involved a literature search and analysis of clinical evidence regarding the use of carglumic acid in patients with propionic and methylmalonic acidurias.

Potential Biases

Potential biases due to the retrospective nature of some studies and variability in CGA dosing.

Limitations

The studies had relatively small sample sizes and lacked formal statistical analysis and controls.

Participant Demographics

Participants included pediatric patients with propionic and methylmalonic acidurias, with ages ranging from neonates to 15 years.

Statistical Information

P-Value

0.0095

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13023-024-03468-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication